NO973241L - Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia, or arteriosclerosis, or for anticoagulant b. - Google Patents

Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia, or arteriosclerosis, or for anticoagulant b.

Info

Publication number
NO973241L
NO973241L NO973241A NO973241A NO973241L NO 973241 L NO973241 L NO 973241L NO 973241 A NO973241 A NO 973241A NO 973241 A NO973241 A NO 973241A NO 973241 L NO973241 L NO 973241L
Authority
NO
Norway
Prior art keywords
treatment
hypertriglyceridemia
hypercholesterolemia
hyperlipidemia
arteriosclerosis
Prior art date
Application number
NO973241A
Other languages
Norwegian (no)
Other versions
NO973241D0 (en
Inventor
Michael Shalmi
Niels Korsgaard
Steven Bain
Birgitte Hjort Guldhammer
Jan Ulrik Weis
Charles E Hart
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO973241L publication Critical patent/NO973241L/en
Publication of NO973241D0 publication Critical patent/NO973241D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse til-veiebringer nye anvendelser av forbin-delser med den generelle formel (I). hvor,oguavhengig av hverandre er hydrogen, hydroksy, halogen, tri-fluormetyl, lavere alkyl, lavere aik-oksy eller (tertiært amino)(lavere alk-oksy); ogoguavhengig av hverandre er hydrogen eller lavere alkyl, eller som et farmasøytisk akseptabelt salt derav, i kombinasjon med en farma-søytisk akseptabel bærer, til fremstil-ling av et farmasøytisk preparat for behandling eller profylakse av hyper-lipoproteinemi, hypertriglyseridemi, hyperlipidemi eller hyperkolesterolemi, eller arteriosklerose, eller for anti-koagulativ behandling.The present invention provides novel uses of compounds of general formula (I). wherein, independently of one another, are hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino) (lower alkoxy); and is independently hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyper-lipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia, or arteriosclerosis, or for anti-coagulant treatment.

NO973241A 1995-01-13 1997-07-11 Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia, or arteriosclerosis, or for anticoagulant b. NO973241D0 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DK4195 1995-01-13
DK4395 1995-01-13
DK6995 1995-01-20
DK77795 1995-06-30
DK76695 1995-06-30
DK76795 1995-06-30
PCT/DK1996/000014 WO1996021443A1 (en) 1995-01-13 1996-01-10 Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis or for anticoagulative treatment

Publications (2)

Publication Number Publication Date
NO973241L true NO973241L (en) 1997-07-11
NO973241D0 NO973241D0 (en) 1997-07-11

Family

ID=27545138

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973241A NO973241D0 (en) 1995-01-13 1997-07-11 Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia, or arteriosclerosis, or for anticoagulant b.

Country Status (11)

Country Link
EP (1) EP0804189A1 (en)
JP (1) JPH10511961A (en)
CN (1) CN1168098A (en)
AU (1) AU4329296A (en)
BR (1) BR9606890A (en)
CA (1) CA2208859A1 (en)
CZ (1) CZ212397A3 (en)
HU (1) HUP9800521A3 (en)
IL (1) IL116745A (en)
NO (1) NO973241D0 (en)
WO (1) WO1996021443A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
WO1999048497A1 (en) * 1998-03-20 1999-09-30 Novo Nordisk A/S USE OF 3,4-DIPHENYLCHROMANS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR LOWERING PLASMA LEVELS OF Lp(a) IN A HUMAN OR SUB-HUMAN PRIMATE
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
ATE532777T1 (en) 2004-09-21 2011-11-15 Marshall Edwards Inc SUBSTITUTED CHROMEDER DERIVATIVES, MEDICATIONS AND APPLICATIONS IN THERAPY
CA2816319C (en) 2010-11-01 2020-06-30 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer
MX368063B (en) 2014-02-07 2019-09-18 Novogen ltd Functionalised benzopyran compounds and use thereof.
HUE054998T2 (en) 2015-02-02 2021-10-28 Mei Pharma Inc Combination therapies for use in the treatment of breast cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1543749A1 (en) * 1966-02-16 1969-12-11 Merck Ag E Process for the preparation of 3,4-cis-4-aryl-isoflavans
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
EP0804189A1 (en) 1997-11-05
IL116745A0 (en) 1996-05-14
WO1996021443A1 (en) 1996-07-18
BR9606890A (en) 1997-10-28
MX9705214A (en) 1997-10-31
CA2208859A1 (en) 1996-07-18
CZ212397A3 (en) 1997-11-12
JPH10511961A (en) 1998-11-17
CN1168098A (en) 1997-12-17
IL116745A (en) 1999-12-22
HUP9800521A3 (en) 1999-12-28
NO973241D0 (en) 1997-07-11
AU4329296A (en) 1996-07-31
HUP9800521A2 (en) 1998-12-28

Similar Documents

Publication Publication Date Title
PT863875E (en) NEW COMPOUNDS 4- (OXIALCOXYPHENYL) -3-OXY-PIPERIDINE FOR THE TREATMENT OF CARDIAC AND RENAL FAILURE
SE8902326L (en) CARBOXAMIDE COMPOUNDS, PROCEDURES FOR THE PREPARATION OF THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
NZ325449A (en) Naphthyl-substituted benzimidazole derivatives as anticoagulants
BR0215240A (en) Calcium derivatives and their use in treating diseases
ATE306261T1 (en) ANTITHROMBOTIC AGENTS
NO20050073L (en) Ring-substituted diphenyllazetidinones, their preparation, their use, and drugs containing the compounds
YU56995A (en) ONLY DERIVED INDOLA
AP9701041A0 (en) Pyridylpyrrole compounds.
BR9611400A (en) "benzoxazine antimycobic agents".
MX9605741A (en) (r)-(-)-2-{n-[4-(1,1-dioxide-3-oxo-2,3-dihydro-benzisotiazole-2-yl)-buty l]-aminomethyl}-cromane crystalline chlorhydrate.
DK0874812T3 (en) New 2,3,5-trimethyl-4-hydroxyanilide derivatives, their preparation and therapeutic use thereof
NO973241L (en) Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia, or arteriosclerosis, or for anticoagulant b.
NO971625L (en) Novel peptides with immunomodulatory effects
MX9708696A (en) Antibacterial cephalosporins.
NO983178L (en) Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
DK26289D0 (en) USE OF 1,4-DISUBSTITUTED PIPERIDINYL FOR THE PREPARATION OF A PHARMACEUTICAL PREPARATION FOR TREATING INSOMNIA
FI844333L (en) 11-SUBSTITUERADE 5H, 11H-PYRROLO / 2,1-C / / 1,4 / BENZOXAZEPINER, FOERFARANDE FOER DERAS FRAMSTAELLNING OCH DERAS ANVAENDNING SOM LAEKEMEDEL.
DK0701449T3 (en) Process for the preparation of an oral solid dosage form containing diclofenac
NO973340L (en) Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of obesity
DE69132578D1 (en) Cephem derivatives
ES2102295B1 (en) NEW COMPOUNDS DERIVED FROM N-BENZOILMETIL-PIPERIDINA.
BR9610175A (en) Compound preparation process of the pharmaceutical composition and use of the compound
NO973242L (en) Use of 3,4-diphenylchromanes for the preparation of a pharmaceutical composition for the treatment or prophylaxis of idiopathic or physiological gynecomastia
ATE216883T1 (en) USE OF 4-PHENYL-3,6-DIHYDRO-2H-PYRIDYL DERIVATIVES AS NMDA RECEPTOR SUBTYPE BLOCKERS
SE0102058D0 (en) New Salts II